EP 0639225 A1 19950222 - NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY.
Title (en)
NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY.
Title (de)
POLYPEPTIDE UND PEPTIDE DAFÜR KODIERENDE NUKLEINSAÜRE UND IHRE VERWENDUNG IM ZUSAMMENHANG MIT TUMORTHERAPIE, ENTZÜNDUNG ODER IMMUNOLOGY.
Title (fr)
NOUVEAUX POLYPEPTIDES ET PEPTIDES, ACIDES NUCLEIQUES CODANT POUR CEUX-CI, ET LEUR EMPLOI EN THERAPIE DES TUMEURS, EN INFLAMMATION OU EN IMMUNOLOGIE.
Publication
Application
Priority
- EP 93909852 A 19930428
- EP 9301022 W 19930428
- EP 92401231 A 19920430
Abstract (en)
[origin: US2002069422A1] The invention relates: to a polypeptide containing in its peptidic chain the amino acid sequence of 311 amino acids of FIG. 3, or a fragment of this sequence, with said fragment being such that it is liable to produce antibodies capable of forming a complex with the amino acid sequence of FIG. 3, or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90% with the amino acid sequence of FIG. 3, and to pharmaceutical compositions containing, as active substance, at least one of the polypeptides of the invention or of the antagonists of the polypeptides of the invention as antitumor compounds, or antiinflammatory compounds or as growth activators of T-cells and B-cells, as bone repair compounds as inducer of immunosuppressive cells, as inhibitors of anti-colony stimulating factor; or as trypoanocidal agents; or part of the polypeptides of the invention, capable of binding to the above-defined receptor.
IPC 1-7
C12N 15/19; C12P 21/02; A61K 38/00; C12N 15/11; C07K 14/00; C12N 15/00; C12P 21/08; A01K 67/027
IPC 8 full level
A01K 67/027 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61P 7/00 (2006.01); A61P 29/00 (2006.01); A61P 33/02 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01); A61P 43/00 (2006.01); C07K 1/20 (2006.01); C07K 14/00 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); C07K 14/555 (2006.01); C07K 14/57 (2006.01); C07K 16/00 (2006.01); C07K 19/00 (2006.01); C12N 1/21 (2006.01); C12N 5/02 (2006.01); C12N 15/00 (2006.01); C12N 15/11 (2006.01); C12N 15/19 (2006.01); C12P 21/02 (2006.01); C12P 21/08 (2006.01)
CPC (source: EP US)
A61P 7/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 33/02 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 14/52 (2013.01 - EP US); C07K 14/525 (2013.01 - EP US); A01K 2217/05 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US); C07K 2319/75 (2013.01 - EP US); C07K 2319/91 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9322437 A1 19931111; AT E226250 T1 20021115; DE 69332406 D1 20021121; DE 69332406 T2 20030626; DK 0639225 T3 20030217; EP 0639225 A1 19950222; EP 0639225 B1 20021016; ES 2185630 T3 20030501; JP H07502171 A 19950309; PT 639225 E 20030331; US 2002069422 A1 20020606; US 5981277 A 19991109
DOCDB simple family (application)
EP 9301022 W 19930428; AT 93909852 T 19930428; DE 69332406 T 19930428; DK 93909852 T 19930428; EP 93909852 A 19930428; ES 93909852 T 19930428; JP 51891093 A 19930428; PT 93909852 T 19930428; US 29412199 A 19990419; US 31883794 A 19941013